Why Adaptimmune`s Forward Momentum May Be The Perfect Entry Point
(WorldNews Health)

Author`s note: If you`re a member of the Total Pharma Tracker, you can discuss this and other actionable ideas, in addition to gaining access to exclusive daily notes as part of `3 Things in Biotech,` along with Avisol Capital Partners` investing I/O machine. Click that link to try a free trial today! Adaptimmune (ADAP) is a company that hasn`t received a ton of coverage on Seeking Alpha, save for an article postulating a significant rebound for the company from author Looking For Diogenes. So it seems appropriate to take a look at this mid-cap cancer biotech for some signs of promise. Today, I want to lead you through some scientific and financial due diligence on ADAP, placing it into...